TransMedics Group, Inc. — Director's Dealing 2024

May 17, 2024

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: TransMedics Group, Inc. (TMDX)
CIK: 0001756262
Period of Report: 2024-05-15

Reporting Person: Hassanein Waleed H (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2024-05-15	Common Stock	M	8625	$13.28	Acquired	70268	Direct
2024-05-15	Common Stock	S	300	$133.42	Disposed	69968	Direct
2024-05-15	Common Stock	S	2100	$134.69	Disposed	67868	Direct
2024-05-15	Common Stock	S	5481	$135.54	Disposed	62387	Direct
2024-05-15	Common Stock	S	744	$136.26	Disposed	61643	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2024-05-15	Stock Option (Right to Buy)	$13.28	M	8625	Disposed	2032-02-22	Common Stock (8625)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	469359	Indirect

Footnotes

F1: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan entered into on September 6, 2023.

F2: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $133.07 to $133.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $134.05 to $135.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $135.06 to $136.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $136.06 to $136.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F6: The option vests at a rate of 2.0833% of the total number of shares each month until the option is fully vested on February 22, 2026.